GlassScriptPhysician profile
Edward Radatz
NPI 1508850553
$395.85
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $147 · 2021: $128 · 2022: $19.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $89.85 | 2020-2021 | |
| Amarin Pharma, INC. | $84.78 | 2019-2021 | |
| Glaxosmithkline, LLC. | $40.04 | 2020-2021 | |
| Novo Nordisk INC | $35.84 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.02 | 2021 | |
| Abbvie INC. | $19.20 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.98 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.90 | 2021 | |
| Sanofi Pasteur INC. | $13.87 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.05 | 2021 | |
| Allergan, INC. | $12.46 | 2019 | |
| Pfizer INC. | $12.18 | 2019 | |
| Hologic Sales and Service, LLC | $11.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Radatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.